https://www.businesswire.com/news/home/20250610841284/en/U.S.-FDA-Approves-UroGens-ZUSDURI-mitomycin-for-Intravesical-Solution-as-the-First-and-Only-Medication-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire